Comparison between creatine kinase MB, heart-type fatty acid-binding protein, and cardiac troponin T for detecting myocardial ischemic injury after cardiac surgery

Jo, Min Seop; Lee, Jehoon; Kim, Soo‐Young; Kwon, Hi Jeong; Lee, Hae Kyung; Park, Dong Jin; Kim, Yeongsic

doi:10.1016/j.cca.2018.10.040

Cited by 21 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from MI, other cardiovascular etiologies can cause elevation of CK-MB. These include myocarditis [ 19 ], pulmonary embolism [ 20 , 21 ], cardiac trauma [ 22 ], heart transplantation [ 23 ], chemotherapy-induced cardiotoxicity [ 24 ], and cardiac surgery [ 25 ]. However, CK-MB levels in these diseases/conditions do not add significant value to their diagnosis or the prognosis, and often cause confusion in the interpretation of the results [ 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 ].…”

Section: Historic Overview: Early Biomarkers For Cvdsmentioning

confidence: 99%

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Omran

Kyrou

Osman

et al. 2022

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a major healthcare burden on the population worldwide. Early detection of this disease is important in prevention and treatment to minimise morbidity and mortality. Biomarkers are a critical tool to either diagnose, screen, or provide prognostic information for pathological conditions. This review discusses the historical cardiac biomarkers used to detect these conditions, discussing their application and their limitations. Identification of new biomarkers have since replaced these and are now in use in routine clinical practice, but still do not detect all disease. Future cardiac biomarkers are showing promise in early studies, but further studies are required to show their value in improving detection of CVD above the current biomarkers. Additionally, the analytical platforms that would allow them to be adopted in healthcare are yet to be established. There is also the need to identify whether these biomarkers can be used for diagnostic, prognostic, or screening purposes, which will impact their implementation in routine clinical practice.

show abstract

Section: Historic Overview: Early Biomarkers For Cvdsmentioning

confidence: 99%

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Omran

Kyrou

Osman

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, a high negative predictive value of H-FABP test can help to rule out AMI earlier (61), which can reduce hospitalizations and expenses. It is worth mentioning that in 2018, Jo et al proved that H-FABP would be a more useful biomarker to detect myocardial ischemic injury than CK-MB and cTnT (95). Based on the properties of H-FABP, the combination of H-FABP with other biomarkers, for instance, H-FABP at the early stage and cTnI at the late stage of AMI, may achieve better diagnostic and prognostic significance.…”

Section: Cardiac Troponinmentioning

confidence: 99%

Diagnostic and Prognostic Biomarkers for Myocardial Infarction

Pan

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The incidence of myocardial infarction (MI) increases every year worldwide. Better diagnostic and prognostic biomarkers for clinical applications are the consistent pursuit of MI research. In addition to electrocardiogram, echocardiography, coronary angiography, etc., circulating biomarkers are essential for the diagnosis, prognosis, and treatment effect monitoring of MI patients. In this review, we assessed both strength and weakness of MI circulating biomarkers including: (1) originated from damaged myocardial tissues including current golden standard cardiac troponin, (2) released from non-myocardial tissues due to MI-induced systems reactions, and (3) preexisted in blood circulation before the occurrence of MI event. We also summarized newly reported MI biomarkers. We proposed that the biomarkers preexisting in blood circulation before MI incidents should be emphasized in research and development for MI prevention in near future.

show abstract

“…Acute myocardial infarction (AMI) mainly occurs upon coronary occlusion, which is caused by detachment and rupture of unstable atherosclerotic plaques (3,4). At present, percutaneous coronary intervention (5), coronary artery bypass grafting (6,7) or thrombolytic therapy (8) are effective treatments against AMI, which work by restoring blood perfusion and oxygen supply. However, coronary reperfusion can cause secondary damage to ischemic tissues, which is known as myocardial ischemia reperfusion injury (MIRI).…”

Section: Introductionmentioning

confidence: 99%

Combination of the ginsenosides Rb3 and Rb2 exerts protective effects against myocardial ischemia reperfusion injury in rats

Liu

Jiang

et al. 2019

Int J Mol Med

View full text Add to dashboard Cite

Ginsenoside Rb3 (G-Rb3) has been demonstrated to alleviate myocardial ischemia reperfusion injury (MIRI); however, it is difficult to separate G-Rb2 from its isomer G-Rb3. The current study aimed to compare the cardioprotective effects of G-Rb3 and the concomitant use of G-Rb3 and G-Rb2 (G-Rb3/Rb2) on MIRI in rats. A rat model of MIRI was established by ligation of the left anterior descending coronary artery and the rats were randomly divided into five groups. Prior to MIRI, G-Rb3/Rb2 (20 mg/kg), G-Rb3 (20 mg/kg) and diltiazem (DLZ; 20 mg/kg, as a positive control) were orally administered to the rats once a day for 3 consecutive days. After 30 min of ischemia and 120 min of reperfusion, cardiac function, infarct size, cardiac marker enzymes, antioxidative parameters, inflammatory factors, histopathological changes, cardiomyocyte apoptosis, and B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein and caspase-3 expression were determined using a multi-channel physiological recording system, nitrotetrazolium blue chloride, biochemical kits, radioimmunoassay kits, hematoxylin and eosin, terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling assay, immunohistochemistry and reverse transcription-quantitative PCR, respectively. The results indicated that treatment with G-Rb3/Rb2 significantly protected rats against MIRI, as shown by improved cardiac function, reduced myocardial ischemic area, decreased serum activities of aspartate aminotransferase, lactate dehydrogenase and creatine kinase MB, decreased serum concentrations of interleukin-6 and tumor necrosis factor-α, decreased malondialdehyde concentration in myocardial tissues, increased activities of superoxide dismutase, glutathione peroxidase and catalase in myocardial tissues, reduced histopathological changes in myocardial tissues, reduced number of apoptotic cardiomyocytes, and changes in the expression levels of caspase-3, Bcl-2 and Bax. In addition, the effects of treatment with G-Rb3/Rb2, G-Rb3 or DLZ were equivalent. The protective effects of G-Rb3/Rb2 on MIRI were similar to those of G-Rb3 in terms of oxidative stress, inflammatory factors and inhibition of cardiomyocyte apoptosis. Therefore, G-Rb3/Rb2 may be developed as a concomitant treatment for MIRI.

show abstract

Comparison between creatine kinase MB, heart-type fatty acid-binding protein, and cardiac troponin T for detecting myocardial ischemic injury after cardiac surgery

Cited by 21 publications

References 35 publications

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future

Diagnostic and Prognostic Biomarkers for Myocardial Infarction

Combination of the ginsenosides Rb3 and Rb2 exerts protective effects against myocardial ischemia reperfusion injury in rats

Contact Info

Product

Resources

About